Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have earned a consensus rating of “Moderate Buy” from the five research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $10.00.

A number of brokerages have weighed in on VTYX. Oppenheimer reissued an “outperform” rating and set a $9.00 target price (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. Wells Fargo & Company dropped their price objective on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Canaccord Genuity Group decreased their target price on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Finally, HC Wainwright reiterated a “neutral” rating and set a $6.00 price target on shares of Ventyx Biosciences in a research report on Monday, November 11th.

Ventyx Biosciences Stock Performance

Shares of VTYX stock opened at $2.65 on Friday. The stock has a market capitalization of $187.38 million, a price-to-earnings ratio of -1.12 and a beta of 0.37. The company’s 50-day simple moving average is $2.20 and its 200-day simple moving average is $2.62. Ventyx Biosciences has a one year low of $1.67 and a one year high of $11.48.

Insider Buying and Selling at Ventyx Biosciences

In other news, CEO Raju Mohan bought 238,248 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The shares were purchased at an average price of $1.83 per share, with a total value of $435,993.84. Following the completion of the acquisition, the chief executive officer now directly owns 1,913,276 shares in the company, valued at approximately $3,501,295.08. This trade represents a 14.22 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 18.18% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ventyx Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of VTYX. Barclays PLC raised its holdings in shares of Ventyx Biosciences by 273.1% in the 3rd quarter. Barclays PLC now owns 80,295 shares of the company’s stock worth $175,000 after purchasing an additional 58,776 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Ventyx Biosciences by 5.9% in the third quarter. Geode Capital Management LLC now owns 1,391,702 shares of the company’s stock valued at $3,034,000 after buying an additional 77,350 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Ventyx Biosciences during the 3rd quarter valued at $246,000. State Street Corp boosted its stake in shares of Ventyx Biosciences by 0.8% during the 3rd quarter. State Street Corp now owns 1,187,650 shares of the company’s stock worth $2,589,000 after acquiring an additional 9,783 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its holdings in shares of Ventyx Biosciences by 19.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 568,479 shares of the company’s stock worth $1,239,000 after acquiring an additional 92,753 shares during the last quarter. 97.88% of the stock is owned by institutional investors and hedge funds.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.